ARTICLE | Clinical News

Enzon Inc. preclinical data

September 19, 1994 7:00 AM UTC

The Piscataway, N.J., company presented additional animal data on the use of its polyethylene glycol-disguised pig hemoglobin, supporting its ability to enhance radiation therapy of tumors. The data supplemented that presented at a Boston blood substitutes meeting in July.

At the Washington, D.C., conference on Blood Substitutes and Related Products, ENZN showed that rats implanted with human tumors and then treated with PEG-hemoglobin had 40 percent less tumor mass after radiation therapy than controls. The oxygen tension in the tumors increased two to three fold, as measured at the tumor surface and in its core, the company reported. ...